Early Tumor Shrinkage as a Predictor of Favorable Treatment Outcomes in Patients With Extensive-Stage SCLC Who Received Programmed Cell Death-Ligand 1 Inhibitor Plus Platinum-Etopo... by Masaki Ishida, MD, Kenji Morimoto, MD, PhD, Tadaaki Yamada, MD, PhD, Takayuki Takeda, MD, PhD, Shinsuke Shiotsu, MD, PhD, Koji Date, MD, Taishi Harada, MD, Nobuyo Tamiya, MD, PhD, Yusuke Chihara, MD, PhD, Yoshizumi Takemura, MD, PhD, Takahiro Yamada, MD, PhD, Hibiki Kanda, MD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Koichi Takayama, MD, PhD

Get full text

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective... by Yuki Katayama, MD, PhD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, PhD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, Koichi Takayama, MD, PhD

Get full text

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study by Yuki Katayama, MD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Akihiro Yoshimura, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, Koichi Takayama, MD, PhD

Get full text